John F. Weidenbruch
Plus aucun poste en cours
Profil
John F.
Weidenbruch worked as a Senior Associate General Counsel at Amgen, Inc. from 1995 to 2005.
He then worked as the General Counsel at Abraxis BioScience, Inc. in 2005 and as the Executive Vice President & General Counsel at Idenix Pharmaceuticals LLC from 2006 to 2010.
From 2010 to 2015, he worked as the General Counsel at Biogen, Inc. and from 2015 to 2017, he worked as the Secretary & General Counsel at Visterra, Inc. He is currently the Secretary, Senior Vice President & General Counsel at Epizyme, Inc. since 2017.
He also served as a Trustee at American Kidney Fund, Inc. Mr. Weidenbruch received his undergraduate degree from Loyola University Maryland, Inc. in 1983 and his graduate degree from Georgetown University Law Center in 1986.
Anciens postes connus de John F. Weidenbruch
| Sociétés | Poste | Fin |
|---|---|---|
| EPIZYME, INC. | General Counsel | 01/10/2022 |
| VISTERRA INC | General Counsel | 01/08/2017 |
| BIOGEN INC. | General Counsel | 01/07/2015 |
| IDENIX PHARMACEUTICALS INC | General Counsel | 01/09/2010 |
Abraxis BioScience, Inc.
 Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | General Counsel | 01/09/2006 |
Formation de John F. Weidenbruch
| Loyola University Maryland, Inc. | Undergraduate Degree |
| Georgetown University Law Center | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Idenix Pharmaceuticals LLC
 Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | Health Technology |
Visterra, Inc.
 Visterra, Inc. Pharmaceuticals: MajorHealth Technology Visterra, Inc. Is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of antibody-based therapies for kidney diseases, and other chronic diseases. It focuses on its research technology platform, HIEROTOPE technology. The company was founded by Alan L. Crane, Kevin J. Bitterman and Ram Sasisekharan on December 20, 2007 and is headquartered in Waltham, MA. | Health Technology |
American Kidney Fund, Inc.
 American Kidney Fund, Inc. Medical/Nursing ServicesHealth Services The American Kidney Fund provides treatment and financial assistance to patients with chronic kidney disease. It also provides assistance with expenses that insurance will not cover, such as transportation to dialysis, medications, special diet, kidney donor expenses, and other treatments. It also conducts specialty programs that help patients afford treatment during emergency travel and recover from natural disasters. The company was founded in 1971, and is headquartered in Rockville, MD. | Health Services |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
